Biotechnology companies are increasingly focusing on enhancing the value of existing oncology therapies through advanced drug delivery technologies, such as nanoparticle-based platforms and intravenous reformulation strategies. This shift, driven by rising drug development costs and regulatory challenges, aims to improve the bioavailability and dosing reliability of established cancer treatments. Oncotelic Therapeutics is at the forefront with its Sapu003 program and Deciparticle platform, which leverage nanotechnology and artificial intelligence to optimize therapeutic applications. The industry is moving toward scalable, platform-based models that emphasize multi-therapeutic capabilities over single-asset development, reflecting a broader trend in the life sciences sector. As interest grows in these innovative approaches, companies are expected to attract more investment, driving advancements in precision medicine and cancer care.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://investingnews.com/platform-biotech-models-draw-investor-eyes-as-drug-delivery-markets-head-toward-410-billion/
